Business context and reporting period
This is Lion Biotechnologies, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2016. The filing issuer name differs from the supplied company metadata, which identifies Iovance Biotherapeutics, Inc.
Lion was a clinical-stage biotechnology company developing autologous tumor-infiltrating lymphocyte (TIL) cell therapies for cancer. Its lead candidate, LN-144, was in a Phase 2 trial for refractory metastatic melanoma; the company reported no commercial products or biopharmaceutical revenue.
Key financial metrics
Amounts below are in millions of dollars, except per-share data and percentages.
| Metric | Q1 2016 / March 31, 2016 | Comparable period / December 31, 2015 |
|---|---|---|
| Revenue | $0 | $0 in Q1 2015 |
| Research and development expense | $4.192 | $2.398 in Q1 2015 |
| General and administrative expense | $2.818 | $2.900 in Q1 2015 |
| Net loss | $6.884 | $5.298 in Q1 2015 |
| Basic and diluted loss per share | $0.14 | $0.14 in Q1 2015 |
| Net cash used in operating activities | $4.552 | $3.459 in Q1 2015 |
| Cash, money market funds, and short-term investments | $99.166 | $103.700 at December 31, 2015 |
| Working capital | $97.5 | Not stated for the comparable date |
| Total liabilities | $1.830, all current | $1.630 at December 31, 2015 |
There was no meaningful revenue-based margin to assess. The company reported no long-term debt, bank credit lines, or off-balance-sheet arrangements. Cash and cash equivalents alone were $8.943 million; short-term investments were $60.251 million. Comprehensive loss was $6.864 million, including a $0.020 million unrealized investment gain.
Material changes versus the prior comparable period
- R&D expense increased $1.794 million, or 75%, principally due to expanded research, the Tampa facility, hiring, and initiation of the Phase 2 trial.
- Net loss increased $1.586 million. G&A expense decreased by $0.082 million, while interest income was $0.126 million in Q1 2016.
- Operating cash use rose by approximately $1.1 million. Investing activities used $0.147 million, compared with $0.782 million in Q1 2015.
- Financing provided no cash in Q1 2016; Q1 2015 financing provided $70.612 million, primarily from a public offering and warrant exercises.
- Stock-based compensation totaled $1.779 million, versus $1.467 million in Q1 2015. The company reclassified $0.3 million of 2015 stock compensation from G&A to R&D, with no effect on total expense or net loss.
Outlook, risks, contingencies, and unusual items
- Management expected 2016 cash spending of $30–$35 million, with higher clinical, research, staffing, and NCI CRADA costs. It believed available funds would cover anticipated operating expenses for at least 12 months from March 31, 2016.
- The company did not anticipate revenue from product sales or licensing in 2016 and expected continuing losses and higher R&D spending.
- Annual guaranteed commitments under license and research agreements were approximately $2.1 million for 2016. License agreements include potential royalties and clinical or regulatory milestone payments; none of the specified milestones requiring lump-sum payment was achieved in Q1.
- The SEC investigation concerned, in part, conduct of a former CEO related to articles about the company. Lion described a proposed settlement framework, but terms and SEC approval remained unresolved; a possible financial penalty was not accrued because its existence and amount were unknown.
- A lawsuit filed April 8, 2016 alleged unpaid advances and related securities rights and sought damages exceeding $1.5 million, plus interest and attorneys’ fees. The company said it was investigating and intended to defend the case.
- Management reported no material changes to previously disclosed risk factors. It cited clinical development, patient enrollment, safety and efficacy, manufacturing, competition, and commercial viability as factors affecting development costs and success.
- Disclosure controls were assessed as effective at quarter-end, with no material change in internal control over financial reporting reported during the quarter.
Important facts for investors to verify
- Confirm the issuer identity and relationship between the filing’s Lion Biotechnologies, Inc. name and the Iovance metadata.
- Track LN-144 Phase 2 enrollment, safety, efficacy, and trial timing, as well as progress in other TIL indications.
- Monitor cash use against the $30–$35 million 2016 spending estimate and management’s stated 12-month funding assessment.
- Follow resolution of the SEC settlement, including whether a penalty is imposed, and the outcome and exposure of the Solomon Capital lawsuit.
- Review future R&D, stock-based compensation, license commitments, and potential milestone or royalty obligations.